Image Source: Unsplash

An Introduction

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies in the munKNEE Psychedelic Compound Based Clinical-Stage Drug Stocks Portfolio with their stock performances last week, in descending order, and their areas of focus, along with their latest news, analyses and commentary where available.

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. (Source)

1.  Compass Pathways (CMPS): down 5.4% last week
   • focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
2. atai Life Sciences (ATAI): down 11.5% last week
   • focuses on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
3. GH Research (GHRS): down 15.1% last week
   • focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
4. Mind Medicine (MNMD): down 17.6% last week
   • focuses on the use of LSD and MDMA. Go here for much more extensive information on LSD and here for much more extensive information on MDMA.

Summary

On average, the above 4 stocks were down 13.0% last week but remain UP 41.1% YTD.

More By This Author:

Pure Play Quantum Computing Portfolio Down 3% In May
Pure Play Cybersecurity Software Stocks Portfolio Down Almost 4% In May
Pure-Play Cloud Computing SaaS Stocks Portfolio Down 15% In May